Clinical Trial Stages

Clinical Trials related to Prostate Cancer treatment recruiting in San Diego California

ChatGPT search

Here are the details for each clinical trial, including NCT numbers, URLs, and contact information:

1. Cabozantinib and Nivolumab in Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT04631744
Description: This Phase 2, multicenter, single-arm study evaluates the combination of cabozantinib and nivolumab in patients with advanced castration-resistant prostate cancer.
Location: La Jolla, California.
Eligibility: Males aged 18 years and older.
More Information: Cabozantinib and Nivolumab Trial
Contact: UC San Diego Health
- Phone: 858-657-7000
- Website: UC San Diego Health - High-Risk Prostate Cancer Clinic

2. ART-Pro: Evaluating Advanced MRI Techniques for Prostate Cancer Detection

NCT Number: NCT04815876
Description: A multicenter trial assessing advanced MRI methods to improve the detection of clinically significant prostate cancer.
Location: San Diego, California.
Eligibility: Males aged 18 years and older.
More Information: ART-Pro Clinical Trial
Contact: UC San Diego Health
- Phone: 858-657-7000
- Website: UC San Diego Health - High-Risk Prostate Cancer Clinic

3. Focal Therapy for Localized Prostate Cancer

NCT Number: NCT02243033
Description: A prospective registry and longitudinal study designed to measure outcomes of prostate cancer patients undergoing focal therapy.
Location: La Jolla, California.
Eligibility: Males aged 18 years and older.
More Information: Focal Therapy Clinical Trial
Contact: UC San Diego Health
- Phone: 858-657-7000
- Website: UC San Diego Health - High-Risk Prostate Cancer Clinic

4. Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy

NCT Number: NCT04030559
Description: This Phase 2 open-label trial evaluates the efficacy and safety of neoadjuvant olaparib combined with an LHRH agonist before radical prostatectomy in men with unfavorable intermediate-risk or high-risk localized prostate cancer.
Location: La Jolla, California.
Eligibility: Males aged 18 years and older with confirmed germline or somatic select HRR alterations.
More Information: Neoadjuvant PARP Inhibition Trial
Contact: UC San Diego Health
- Phone: 858-657-7000
- Website: UC San Diego Health - High-Risk Prostate Cancer Clinic

5. Genesis Research LLC Clinical Trials

Description: Genesis Research is actively recruiting volunteers for clinical trials focusing on prostate cancer, benign prostatic hyperplasia (BPH), bladder cancer, and bone health after hormone therapy.
Location: Encinitas, California.
Contact: Genesis Research LLC
- Phone: (858) 429-7050
- Website: Genesis Research LLC Clinical Studies

If you're interested in participating in any of these trials, please reach out to the respective contact points for detailed eligibility criteria and enrollment procedures.

UCSD Health Prostate Cancer Search

Prostate Cancer clinical trials at UCSD

43 in progress, 19 open to eligible people

XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
open to eligible people ages 18 years and up
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
La Jolla, California and other locations
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
open to eligible males ages 18 years and up
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called Restriction Spectrum…
La Jolla, California
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
open to eligible males ages 18-90
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T…
San Diego, California and other locations
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
open to eligible males ages 18 years and up
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body.…
La Jolla, California and other locations
Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
open to eligible males ages 18 years and up
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
La Jolla, California and other locations
Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
open to eligible males ages 18 years and up
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized…
La Jolla, California and other locations
Oral MRT-2359 in Selected Cancer Patients
open to eligible people ages 18 years and up
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site,…
San Diego, California and other locations
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
open to eligible people ages 18 years and up
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and …
La Jolla, California and other locations
TERPS Trial for De Novo Oligometastic Prostate Cancer
open to eligible males ages 18 years and up
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
La Jolla, California and other locations
Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
open to eligible people ages 21 years and up
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower …
Encinitas, California and other locations
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
open to eligible males ages 18 years and up
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and…
La Jolla, California and other locations
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
open to eligible males ages 18 years and up
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense…
Encinitas, California and other locations
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
open to eligible males ages 18 years and up
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness.…
Encinitas, California and other locations
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
open to eligible males ages 18 years and up
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have…
San Diego, California and other locations
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
open to eligible males ages 18 years and up
This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The…
San Diego, California and other locations
Focal Therapy for Localized Prostate Cancer
open to eligible males ages 18 years and up
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
La Jolla, California
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
open to eligible males ages 21 years and up
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The…
San Diego, California and other locations
Precision-Based Genomics in Prostate Cancer
open to eligible males ages 18 years and up
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how…
La Jolla, California and other locations
Prostate Assessment With Restriction Spectrum Imaging (RSI) MRI
open to eligible males ages 18 years and up
This single-center study will enroll 40 male participants to complete 2 diffusion magnetic resonance images within 30 days of each other.
La Jolla, California
In Progress, Not Accepting New Patients
Outcomes With Proton and Photon Radiation in Prostate Cancer
Sorry, in progress, not accepting new patients
This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy…
La Jolla, California and other locations
Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Sorry, in progress, not accepting new patients
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
San Diego, California and other locations
Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally…
La Jolla, California and other locations
International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen …
La Jolla, California and other locations
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III…
La Jolla, California and other locations
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
Sorry, in progress, not accepting new patients
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed …
La Jolla, California and other locations
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Sorry, in progress, not accepting new patients
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate …
La Jolla, California and other locations
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x …
San Diego, California and other locations
Improving Germline Testing in At-Risk Patients With Prostate Cancer
Sorry, in progress, not accepting new patients
A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational session.
La Jolla, California
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Sorry, in progress, not accepting new patients
This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the…
La Jolla, California and other locations
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Sorry, in progress, not accepting new patients
This multicenter randomized phase II trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).
La Jolla, California and other locations
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Sorry, in progress, not accepting new patients
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: - Androgen…
La Jolla, California and other locations
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Sorry, in progress, not accepting new patients
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary…
La Jolla, California and other locations
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Sorry, in progress, not accepting new patients
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
San Diego, California and other locations
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen…
La Jolla, California and other locations
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by …
San Diego, California and other locations
Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Sorry, in progress, not accepting new patients
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
San Diego, California and other locations
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Sorry, in progress, not accepting new patients
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
La Jolla, California and other locations
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Sorry, in progress, not accepting new patients
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill…
La Jolla, California and other locations
Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Sorry, currently not accepting new patients, but might later
This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.
La Jolla, California and other locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Sorry, in progress, not accepting new patients
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue,…
La Jolla, California and other locations
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Sorry, in progress, not accepting new patients
This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body…
La Jolla, California and other locations
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA …
La Jolla, California and other locations
Observational Study of Patients Being Treated with ORGOVYX
Sorry, in progress, not accepting new patients
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine…
La Jolla, California and other locations